- Conditions
- Carotid Artery Diseases, Stroke, Cerebral Arteriosclerosis
- Interventions
- WALLSTENT® Endoprosthesis™
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 747 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Mountain View, California + 41 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 5,351
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes
- Interventions
- tesaglitazar
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 55 more
- Conditions
- Obsessive-Compulsive Disorder, Tricholemmoma, Skin-Picking
- Interventions
- Computerized cognitive training, Computerized placebo training
- Behavioral
- Lead sponsor
- University of Wisconsin, Milwaukee
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Stroke, Aphasia
- Interventions
- Schedule of tDCS administration
- Device
- Lead sponsor
- Kessler Foundation
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- West Orange, New Jersey • Milwaukee, Wisconsin
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
- Interventions
- Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 3,154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2021
- U.S. locations
- 208
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
- Conditions
- ATM Gene Mutation, ATR Gene Mutation, BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, FANCC Gene Mutation, FANCD2 Gene Mutation, FANCF Gene Mutation, FANCM Gene Mutation, NBN Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, RPA1 Gene Mutation, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Other · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1151
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 713 more
- Conditions
- HIV Infections
- Interventions
- Face-to-face training, Distance training, Popular Opinion Leader (POL)
- Behavioral
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2019
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
- Interventions
- Laboratory Biomarker Analysis, Polyvalent Antigen-KLH Conjugate Vaccine, Saponin-based Immunoadjuvant OBI-821
- Other · Biological
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 46
- States / cities
- Mobile, Alabama • Orange, California • Palo Alto, California + 38 more
- Conditions
- Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
- Interventions
- Ciclesonide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 41
- States / cities
- Encinitas, California • Huntington Beach, California • Long Beach, California + 36 more
- Conditions
- Early Breast Cancer
- Interventions
- Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 69 more
- Conditions
- Crohn's Disease
- Interventions
- Cx601, Placebo
- Drug · Other
- Lead sponsor
- Tigenix S.A.U.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 568 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 68
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 51 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
- Conditions
- Heart Failure
- Interventions
- DuraHeart Left Ventricular Assist System (LVAS)
- Device
- Lead sponsor
- Terumo Heart Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 20 more
- Conditions
- Lung Cancer Metastatic, NSCLC Stage IV, Adenocarcinoma of Lung
- Interventions
- Pembrolizumab, Bemcentinib
- Drug
- Lead sponsor
- BerGenBio ASA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • Milwaukee, Wisconsin
- Conditions
- Diabetic Gastroparesis
- Interventions
- CIN-102 Dose 15mg or 10mg, Placebo
- Drug
- Lead sponsor
- CinDome Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 100
- States / cities
- Dothan, Alabama • Foley, Alabama • Huntsville, Alabama + 82 more
- Conditions
- Crohn Disease
- Interventions
- GED-0301, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 136
- States / cities
- Litchfield Park, Arizona • Mesa, Arizona • Phoenix, Arizona + 107 more
- Conditions
- Transgender, Transgenderism
- Interventions
- Not listed
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 12 Years to 30 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Breast Cancer
- Interventions
- 3-dimensional conformal accelerated partial breast irradiation, brachytherapy, whole breast irradiation, MammoSite or other single-entry intracavitary device
- Radiation
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4,216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2018
- U.S. locations
- 374
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 295 more
- Conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3), Endocrine Therapy
- Interventions
- Pharmacist delivered symptom monitoring and management
- Behavioral
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Rochester, Minnesota • Milwaukee, Wisconsin
- Conditions
- High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Lenalidomide, Magnetic Resonance Imaging, Obinutuzumab, Positron Emission Tomography, Prednisone, Venetoclax
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 114
- States / cities
- Tucson, Arizona • Los Angeles, California • Derby, Connecticut + 93 more
- Conditions
- Diabetes Mellitus
- Interventions
- Alogliptin, Pioglitazone, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 655 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 83
- States / cities
- Columbiana, Alabama • Hueytown, Alabama • Huntsville, Alabama + 80 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- creatine, tamoxifen
- Drug
- Lead sponsor
- Nazem Atassi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 9
- States / cities
- Kansas City, Kansas • Boston, Massachusetts • Worcester, Massachusetts + 6 more
- Conditions
- Exocrine Pancreatic Insufficiency
- Interventions
- RELiZORB, Placebo
- Device
- Lead sponsor
- Alcresta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 45 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Boise, Idaho • Indianapolis, Indiana + 8 more
- Conditions
- Endometrial Cancer
- Interventions
- Enfortumab Vedotin
- Drug
- Lead sponsor
- William Bradley
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin